Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),
and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).